Gwo Xi Stem Cell has established partnerships with multiple veterinary clinics, veterinary associations, and distribution partners to build a comprehensive veterinary regenerative medicine network, while continuously expanding its presence in the market.
Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) announced on December 9 that it has obtained the results of its Phase I human clinical trial for type I diabetes in collaboration with Vietnam.
Looking ahead, Dr. Ming-His Chuang explained that Gwo Xi Stem Cell’s primary strategy is to prioritize domestic drug approval, while pursuing out-licensing and strategic partnerships internationally.